Jing-Houng Wang1, Hsin-You Ou2, Yi-Hao Yen1, Chien-Hung Chen1, Sheng-Nan Lu3,4. 1. Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123, Ta Pei Road, Niao Sung 833, Kaohsiung City, Taiwan. 2. Department of Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung City, Taiwan. 3. Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123, Ta Pei Road, Niao Sung 833, Kaohsiung City, Taiwan. juten@ms17.hinet.net. 4. Division of Hepato-Gastroenterology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi County, Taiwan. juten@ms17.hinet.net.
Abstract
BACKGROUND: Controlled attenuation parameter (CAP) has been developed to estimate the extent of hepatic steatosis. AIMS: The purpose was to evaluate the usefulness of CAP in assessing hepatic steatosis and its change using magnetic resonance imaging proton density fat fraction (MRI-PDFF) as reference standard. METHODS: Consecutive patients with liver steatosis were enrolled prospectively. We assessed hepatic steatosis with CAP and MRI-PDFF at enrollment and 12-month follow-up. The correlations between the two methods were analyzed. With MRI-PDFF as reference, the performance of CAP in diagnosis of steatosis severity and its changes was assessed. RESULTS: A total of 50 patients were enrolled, and 45 of them had follow-up MRI-PDFF and CAP at a median interval of 399 days. The mean hepatic steatosis was 13.4% by MRI-PDFF and 291.6 dB/m by CAP. There were positive correlations between CAP and MRI-PDFF in steatosis severity and its change. The median value of CAP was 254, 301.5, and 329.5 dB/m for steatosis < 10%, 10-20%, and > 20%, respectively. For CAP in detecting steatosis ≥ 10% and > 20%, the diagnostic performance was 0.821 and 0.814. With the cutoff of 275 dB/m for ≥ 10% steatosis, the positive predictive value was 84.8%. With the cutoff of 325 dB/m for > 20% steatosis, the negative predictive value was 91.9%. In multiple linear regression, one dB/m change by CAP was associated with 0.039% change by MRI-PDFF. CONCLUSIONS: In assessing liver fat content, CAP correlated with MRI-PDFF and was useful for detection and monitoring of hepatic steatosis.
BACKGROUND: Controlled attenuation parameter (CAP) has been developed to estimate the extent of hepatic steatosis. AIMS: The purpose was to evaluate the usefulness of CAP in assessing hepatic steatosis and its change using magnetic resonance imaging proton density fat fraction (MRI-PDFF) as reference standard. METHODS: Consecutive patients with liver steatosis were enrolled prospectively. We assessed hepatic steatosis with CAP and MRI-PDFF at enrollment and 12-month follow-up. The correlations between the two methods were analyzed. With MRI-PDFF as reference, the performance of CAP in diagnosis of steatosis severity and its changes was assessed. RESULTS: A total of 50 patients were enrolled, and 45 of them had follow-up MRI-PDFF and CAP at a median interval of 399 days. The mean hepatic steatosis was 13.4% by MRI-PDFF and 291.6 dB/m by CAP. There were positive correlations between CAP and MRI-PDFF in steatosis severity and its change. The median value of CAP was 254, 301.5, and 329.5 dB/m for steatosis < 10%, 10-20%, and > 20%, respectively. For CAP in detecting steatosis ≥ 10% and > 20%, the diagnostic performance was 0.821 and 0.814. With the cutoff of 275 dB/m for ≥ 10% steatosis, the positive predictive value was 84.8%. With the cutoff of 325 dB/m for > 20% steatosis, the negative predictive value was 91.9%. In multiple linear regression, one dB/m change by CAP was associated with 0.039% change by MRI-PDFF. CONCLUSIONS: In assessing liver fat content, CAP correlated with MRI-PDFF and was useful for detection and monitoring of hepatic steatosis.
Entities:
Keywords:
Controlled attenuation parameter; Hepatic steatosis; Magnetic resonance imaging proton density fat fraction; Nonalcoholic fatty liver disease
Authors: Mohammad S Siddiqui; Raj Vuppalanchi; Mark L Van Natta; Erin Hallinan; Kris V Kowdley; Manal Abdelmalek; Brent A Neuschwander-Tetri; Rohit Loomba; Srinivasan Dasarathy; Danielle Brandman; Edward Doo; James A Tonascia; David E Kleiner; Naga Chalasani; Arun J Sanyal Journal: Clin Gastroenterol Hepatol Date: 2018-04-26 Impact factor: 11.382
Authors: Thomas Karlas; David Petroff; Magali Sasso; Jian-Gao Fan; Yu-Qiang Mi; Victor de Lédinghen; Manoj Kumar; Monica Lupsor-Platon; Kwang-Hyub Han; Ana C Cardoso; Giovanna Ferraioli; Wah-Kheong Chan; Vincent Wai-Sun Wong; Robert P Myers; Kazuaki Chayama; Mireen Friedrich-Rust; Michel Beaugrand; Feng Shen; Jean-Baptiste Hiriart; Shiv K Sarin; Radu Badea; Kyu Sik Jung; Patrick Marcellin; Carlo Filice; Sanjiv Mahadeva; Grace Lai-Hung Wong; Pam Crotty; Keiichi Masaki; Joerg Bojunga; Pierre Bedossa; Volker Keim; Johannes Wiegand Journal: J Hepatol Date: 2016-12-28 Impact factor: 25.083
Authors: Giovanna Ferraioli; Carlo Filice; Laurent Castera; Byung Ihn Choi; Ioan Sporea; Stephanie R Wilson; David Cosgrove; Christoph F Dietrich; Dominique Amy; Jeffrey C Bamber; Richard Barr; Yi-Hong Chou; Hong Ding; Andre Farrokh; Mireen Friedrich-Rust; Timothy J Hall; Kazutaka Nakashima; Kathryn R Nightingale; Mark L Palmeri; Fritz Schafer; Tsuyoshi Shiina; Shinichi Suzuki; Masatoshi Kudo Journal: Ultrasound Med Biol Date: 2015-03-20 Impact factor: 2.998
Authors: Thuy-Anh Le; Joshua Chen; Christopher Changchien; Michael R Peterson; Yuko Kono; Heather Patton; Benjamin L Cohen; David Brenner; Claude Sirlin; Rohit Loomba Journal: Hepatology Date: 2012-07-02 Impact factor: 17.425
Authors: Hykoush A Asaturyan; Nicolas Basty; Marjola Thanaj; Brandon Whitcher; E Louise Thomas; Jimmy D Bell Journal: PLoS One Date: 2022-09-13 Impact factor: 3.752